These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 12709044)

  • 41. Practical and cost-effective measurement of B-domain deleted and full-length recombinant FVIII in the routine haemostasis laboratory.
    Cauchie M; Toelen J; Peerlinck K; Jacquemin M
    Haemophilia; 2013 May; 19(3):e133-8. PubMed ID: 23374099
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.
    Hermans C; Mahlangu J; Booth J; Schütz H; Santagostino E; Young G; Lee HY; Steinitz-Trost KN; Blanchette V; Berntorp E
    Haemophilia; 2018 May; 24(3):376-384. PubMed ID: 29732708
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.
    Kempton CL; Abshire TC; Deveras RA; Hoots WK; Gill JC; Kessler CM; Key NS; Konkle BA; Kuriakose P; Macfarlane DE; Bergman G
    Haemophilia; 2012 Sep; 18(5):798-804. PubMed ID: 22512291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Summary of the WHO hearing on the development of product-specific reference materials for coagulation factor VIII and factor IX products.
    Ovanesov MV; Williams SC; Nübling CM; Dodt J; Hilger A; Maryuningsih Y; Gray E
    Biologicals; 2020 Sep; 67():88-93. PubMed ID: 32847723
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Does difference between label and actual potency of factor VIII concentrate affect pharmacokinetic-guided dosing of replacement therapy in haemophilia A?
    Goedhart TMHJ; Bukkems LH; van Moort I; Spence CC; Zwaan MC; de Maat MPM; Mathôt RAA; Cnossen MH;
    Haemophilia; 2022 Jul; 28(4):610-618. PubMed ID: 35526235
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Laboratory assay measurement of modified clotting factor concentrates: a review of the literature and recommendations for practice.
    Young GA; Perry DJ;
    J Thromb Haemost; 2019 Apr; 17(4):567-573. PubMed ID: 30667575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prophylactic treatment in Sweden--overtreatment or optimal model?
    Ljung RC
    Haemophilia; 1998 Jul; 4(4):409-12. PubMed ID: 9873762
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management.
    Müller J; Goldmann G; Marquardt N; Pötzsch B; Oldenburg J
    Hamostaseologie; 2020 Nov; 40(S 01):S15-S20. PubMed ID: 33187006
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Factor VIII assay mimicking in vivo coagulation conditions.
    Kusch M; Grundmann C; Keitel S; König H
    Haemophilia; 2014 Mar; 20(2):e164-70. PubMed ID: 24286249
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues.
    Kitchen S; Kershaw G; Tiefenbacher S
    Haemophilia; 2016 Jul; 22 Suppl 5():72-7. PubMed ID: 27405680
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low-dose factor VIII infusion in Chinese adult haemophilia A patients: pharmacokinetics evidence that daily infusion results in higher trough level than with every-other-day infusion with similar factor VIII consumption.
    Hua B; Lee A; Fan L; Li K; Zhang Y; Poon MC; Zhao Y
    Haemophilia; 2017 May; 23(3):417-421. PubMed ID: 28111886
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies.
    Björkman S; Carlsson M; Berntorp E; Stenberg P
    Clin Pharmacokinet; 1992 May; 22(5):385-95. PubMed ID: 1505144
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII.
    Preijers T; van Moort I; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA;
    Thromb Haemost; 2018 Mar; 118(3):514-525. PubMed ID: 29534249
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Considerations on activity assay discrepancies in factor VIII and factor IX products.
    Ovanesov MV; Jackson JW; Golding B; Lee TK
    J Thromb Haemost; 2021 Sep; 19(9):2102-2111. PubMed ID: 34145730
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Issues complicating precision dosing for factor VIII prophylaxis.
    Valentino LA; Turecek PL; Gritsch H; Butenas S; Mann KG
    Transfus Apher Sci; 2018 Aug; 57(4):472-479. PubMed ID: 30139569
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recombinant factor VIII: past, present and future of treatment of hemophilia A.
    Raso S; Hermans C
    Drugs Today (Barc); 2018 Apr; 54(4):269-281. PubMed ID: 29869648
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety of recombinant coagulation factors in treating hemophilia.
    Morfini M; Rapisarda CAP
    Expert Opin Drug Saf; 2019 Feb; 18(2):75-85. PubMed ID: 30681006
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
    Martinowitz U; Bjerre J; Brand B; Klamroth R; Misgav M; Morfini M; Santagostino E; Tiede A; Viuff D
    Haemophilia; 2011 Nov; 17(6):854-9. PubMed ID: 21443634
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Variability in factor VIII concentrate measurement: results from SSC field collaborative studies.
    Raut S; Sands D; Heath AB; Barrowcliffe TW
    J Thromb Haemost; 2003 Sep; 1(9):1927-34. PubMed ID: 12941033
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New products for the treatment of haemophilia.
    Laffan M
    Br J Haematol; 2016 Jan; 172(1):23-31. PubMed ID: 26456702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.